[1] Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol,2020,17(9):557-588. [2] Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol,2021,74(5):1212-1224. [3] Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int,2019,39(1):7-18. [4] Elvevi A, Laffusa A, Scaravaglio M, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol,2022,27(5):100737. [5] Mosconi C, Calandri M, Javle M, et al. Interventional radiology approaches for intra-hepatic cholangiocarcinoma. Chin Clin Oncol,2020,9(1):8-12. [6] Nakamura Y, Higaki T, Honda Y, et al. Advanced CT techniques for assessing hepatocellular carcinoma. Radiol Med,2020,126(7):925-935. [7] Goo HW. Four-Dimensional thoracicCT in free-breathing children. Korean J Radiol,2019,20(1):50-57. [8] Agostini A, Borgheresi A, Bruno F, et al. New advances in CT imaging of pancreas diseases: a narrative review. Gland Surg,2020,9(6):2283-2294. [9] Buus TW, Rasmussen F, Nellemann HM, et al. Comparison of contrast-enhanced CT, dual-layer detector spectral CT, and whole-body MRI in suspected metastatic breast cancer: a prospective diagnostic accuracy study. Eur Radiol,202,31(12):8838-8849. [10] Husmann L, Huellner MW, Gruenig H, et al. Imaging characteristics and diagnostic accuracy of FDG-PET/CT, contrast enhanced CT and combined imaging in patients with suspected mycotic or inflammatory abdominal aortic aneurysms. PLoS One,2022,17(8):272772-272779. [11] Mejia JC, Pasko J. Primaryliver cancers: Intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Surg Clin North Am,2020,100(3):535-549. [12] Macias RIR, Monte MJ, Serrano MA, et al. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY),2021,13(19):23416-23434. [13] Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int,201,39(1):19-31. [14] Dondossola D, Ghidini M, Grossi F, et al. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol,2020,26(25):3542-3561. [15] Lee YT, Wang JJ, Luu M, et al. Comparison of clinical features and outcomes between intrahepatic cholangiocarcinoma and hepatocellular carcinoma in the united states. Hepatology,2021,74(5):2622-2632. [16] Mar WA, Chan HK, Trivedi SB, et al. Imaging ofintrahepatic cholangiocarcinoma. Semin Ultrasound CT MR, 2020,42(4):366-380. [17] Mahmoudi S, Bernatz S, Althoff FC, et al. Dual-energy CT based material decomposition to differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Eur J Radiol,2022,156(1):110556-110562. [18] Wakiya T, Ishido K, Kimura N, et al. CT-based deep learning enables early postoperative recurrence prediction for intrahepatic cholangiocarcinoma. Sci Rep,2022,12(1):8428-8435. [19] Fiz F, Masci C, Costa G, et al. PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival. Eur J Nucl Med Mol Imaging,2022,49(10):3387-3400. [20] Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol,2020,72(1):95-103. [21] Xue B, Wu S, Zhang M, et al. A radiomic-based model of different contrast-enhanced CT phase for differentiate intrahepatic cholangiocarcinoma from inflammatory mass with hepatolithiasis. Abdom Radiol (NY),2021,46(8):3835-3844. [22] Zhao F, Pang G, Li X, et al. Value of perfusion parameters histogram analysis of triphasic CT in differentiating intrahepatic mass forming cholangiocarcinoma from hepatocellular carcinoma. Sci Rep,2021,11(1):23163-23169. |